Background Recently, several animal studies investigated the relation between ALDH2 and cardiac ischaemia /reperfusion injury, but the results were controversial. Meanwhile, no relevant researches on population have been reported. And It is well known that acetaldehyde dehydrogenase 2 (ALDH2) has a significant variation in a single-nucleotide polymorphism of so-called G487A polymorphism in Asian, where the mutant allele is carried by nearly 50% of east Asians which has significant reduced or completely lost catalytic activity than people with ALDH2*1/*1 genotype.
Objective To investigate the association between ALDH2 G487A polymorphism and myocardial ischaemia/reperfusion injury in Chinese.
Methods We serially measured the release of troponin I (cTNI) and creatine kinase MB (CKMB) in 148 patients with acute myocardial infarction. The extent of cardiac injury was divided into two categories, the larger one of which is determined when the peak level of myocardial enzymes exceeded 30ng/ml and 80mg/ml for cTNI and CKMB respectively. Meanwhile, ALDH2 genotype was detected as well as other clinical parameters. Logistic regression analysis was used to analyse the association between the ALDH2 genotypes and myocardial ischaemia /reperfusion injury.
Results In 146 patients with acute myocardial infarction whose myocardial injury was estimated by cTNI (p=0.040) and in patients with STEMI undergoing PCI whose myocardial injury was estimated by cTNI (n=72, p=0.018)and CKMB (n=67, p=0.035) respectively, the proportion of individuals with mutant allele was higher in patients with smaller injury than in that with larger. ALDH2 genetic mutation may be an independent protective factor for patients with acute myocardial infarction undergoing PCI (OR 0.264, p=0.034) and patients with STEMI undergoing PCI (OR 0.264, p=0.034) when injury was assessed by cTNI but not CKMB.
Conclusions ALDH2 G487A polymorphism is possibly associated with myocardial ischaemia/reperfusion injury in Chinese. ALDH2 geneic mutation (G487A) may confer independent cardioprotection in patients with acute myocardial infarction undergoing PCI and those with STEMI undergoing PCI.